|

Nephroprotective Effect of Nicorandil in Type 2 Diabetes Mellitus

RECRUITINGPhase 3Sponsored by Tanta University
Actively Recruiting
PhasePhase 3
SponsorTanta University
Started2023-02-28
Est. completion2025-02
Eligibility
Age18 Years – 60 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06430125

Summary

This study aims to evaluate the possible nephroprotective effect of nicorandil in patients with type 2 diabetes mellitus .

Eligibility

Age: 18 Years – 60 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients newly diagnosed with T2DM with diet control and good glycemic index ( Hb A1C\< 7 )
* Age range between 18 and 60 years old.
* Both sexes.
* Stage 1and Stage 2 CKD according to KDIGO .
* Controlled HTN .

Exclusion Criteria:

* Pregnant and lactating females.
* Patients with hypersensitivity to nicorandil.
* Other Causes of CKD or Nephropathy eg : Uncontrolled HTN , Renal Malignancy , collagen disease as Amyloidosis and some autoimmune disease as ( SLE and Rh.fever ) .
* Uncontrolled HTN and its antihypertensive medications ( ACEI , ARB ) and other antihypertensive medications .
* Patients receiving nephrotoxic drugs as aminoglycosides, non-steroidal anti inflammatory drugs and contrast media.

Conditions2

DiabetesType2 Diabetes Mellitus

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.